Clinical Professor Michael Boyer AM

Clinical Professor
Medicine, Central Clinical School

C39 - Royal Prince Alfred Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 8514 0922
F: +61 2 95157404

W: Related website
Curriculum vitae


Lung cancer; Head and neck cancer

International links

Singapore. (Cancer Therapeutics Research Group) Director of CTRG.


2014 | 2013 | 2012 | 2011 | 2010 | 2009


  • Laurie, S., Solomon, B., Seymour, L., Ellis, P., Goss, G., Shepherd, F., Boyer, M., Arnold, A., Clingan, P., Laberge, F., Fenton, D., Hirsh, V., Zukin, M., Stockler, M., Lee, C., Chen, E., Montenegro, A., Ding, K., Bradbury, P. (2014), Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer. 50(4), 706-712. [Abstract]
  • Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014), Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology. 67(4), 333-340. [Abstract]
  • Ramalingam, S., Janne, P., Mok, T., O'Byrne, K., Boyer, M., Von Pawel, J., Pluzanski, A., Shtivelband, M., Docampo, L., Bennouna, J., Zhang, H., Liang, J., Doherty, J., Taylor, I., Mather, C., Goldberg, Z., O'Connell, J., Paz-Ares, L. (2014), Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 15(12), 1369-1378. [Abstract]
  • Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Mallesara, G., Molloy, P., Horvath, L., Clark, S. (2014), Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer. 111(9), 1802-1809. [Abstract]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Mallesara, G., Gurney, H., Clark, S., Swarbrick, A., Daly, R., Horvath, L. (2014), Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer. 110(10), 2462-2471. [Abstract]
  • Boyer, M., Tsao, M., Jänne, P., Ramalingam, S., Pitman Lowenthal, S., Alam, M. (2014), Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. Asia-Pacific Journal of Clinical Oncology. 10 Suppl 2, 2-10. [Abstract]
  • Tafreshi, A., Thientosapol, E., Liew, M., Guo, Y., Quaggiotto, M., Boyer, M., Davis, I. (2014), Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group. Asia-Pacific Journal of Clinical Oncology. 10(1), 60-65. [Abstract]


  • van Zandwijk, N., Clarke, C., Henderson, D., Musk, A., Fong, K., Nowak, A., Loneragan, R., McCaughan, B., Boyer, M., Feigen, M., Currow, D., Schofield, P., Nick Pavlakis, B., McLean, J., Marshall, H., Leong, S., Keena, V., Penman, A. (2013), Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Journal of Thoracic Disease. 5(6), E254-307. [Abstract]
  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Boyer, M., Stockler, M. (2013), A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer. 81(3), 422-427. [Abstract]
  • Sequist, L., Yang, J., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S., Orlov, S., Tsai, C., Boyer, M., Su, W., Bennouna, J., Kato, T., Gorbunova, V., Lee, K., Shah, R., Massey, D., Zazulina, V., Shahidi, M., Schuler, M. (2013), Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology. 31(27), 3327-3334. [Abstract]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., Kohonen-Corish, M., Fox, S., Cooper, W., Solomon, B. (2013), Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology. 26(12), 1545-1553. [Abstract]
  • Coupe, N., Cox, K., Clark, K., Boyer, M., Stockler, M. (2013), Outcomes of Permanent Peritoneal Ports for the Management of Recurrent Malignant Ascites. Journal of Palliative Medicine. 16(8), 938-940. [Abstract]
  • McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013), Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small cell lung cancer. Internal Medicine Journal. 43(4), 424-429. [Abstract]
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013), Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology. 8(4), 408-414. [Abstract]
  • Spina, R., Chu, S., Chatfield, M., Chen, J., Tin, M., Boyer, M. (2013), Outcomes of Chemoradiation for Patients with Locally Advanced Non-Small-Cell Lung Cancer. Internal Medicine Journal. 43(7), 790-797. [Abstract]
  • Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013), Malignant pleural mesothelioma. Cancer Forum. 37(2), 181-185.


  • Yeo, W., Chung, H., Chan, S., Wang, L., Lim, R., Picus, J., Boyer, M., Mo, F., Koh, J., Rha, S., Hui, E., Jeung, H., Roh, J., Yu, S., To, K., Tao, Q., Ma, B., Chan, A., Tong, J., Erlichman, C., Chan, A., Goh, B. (2012), Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology. 30(27), 3361-3367. [Abstract]
  • Ramalingam, S., Blackhall, F., Krzakowski, M., Barrios, C., Park, K., Bover, I., Seog Heo, D., Rosell, R., Talbot, D., Frank, R., Letrent, S., Ruiz-Garcia, A., Taylor, I., Liang, J., Campbell, A., O'Connell, J., Boyer, M. (2012), Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(27), 3337-3344. [Abstract]
  • Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., Thompson, J. (2012), Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology. 24(9), e131-e136. [Abstract]
  • Boyer, M., Horwood, K., Pavlakis, N., DE Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012), Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology. 8(3), 248-254. [Abstract]
  • Kim, G., Mahoney, M., Szydlo, D., Mok, T., Marshke, R., Holen, K., Picus, J., Boyer, M., Pitot, H., Rubin, J., Philip, P., Nowak, A., Wright, J., Erlichman, C. (2012), An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs. 30(1), 387-394. [Abstract]
  • Dhillon, H., van der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012), The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. BMC Cancer. 12, 572. [Abstract]
  • Yip, P., Barnes, D., McCaughan, B., Boyer, M. (2012), Diagnosis and treatment of lung cancer: A focus on the GP's role. Medicine Today. 13(2), 30-36.


  • Vansteenkiste, J., Solomon, B., Boyer, M., Wolf, J., Miller, N., Di Scala, L., Pylvaenaeinen, I., Petrovic, K., Dimitrijevic, S., Anrys, B., Laack, E. (2011), Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 6(12), 2120-9. [Abstract]
  • Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R., Middleton, G., Eberhardt, W., Szczesna, A., Reiterer, P., Saleh, M., Arrieta, O., Bajetta, E., Webb, R., Raats, J., Benner, R., Fowst, C., Meech, S., Readett, D., Schiller, J. (2011), Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(19), 2667-74. [Abstract]
  • Cox, K., Goel, S., O'Connell, R., Boyer, M., Beale, P., Simes, R., Stockler, M. (2011), A randomised crossover trial comparing inpatient and outpatient administration of high dose cisplatin. Internal medicine journal. (2). [Abstract]
  • Cooper, W., O'toole, S., Boyer, M., Horvath, L., Mahar, A. (2011), What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 43(2), 103-115. [Abstract]
  • Yan, T., Cao, C., Boyer, M., Tin, M., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2011), Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Annals of Thoracic and Cardiovascular Surgery. 17(3), 243-249. [Abstract]


  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010), High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research. 16(23), 5805-5813. [Abstract]
  • Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010), A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer chemotherapy and pharmacology. 66(5), 845-50. [Abstract]
  • Grimison, P., Stockler, M., Thomson, D., Olver, I., Harvey, V., Gebski, V., Lewis, C., Levi, J., Boyer, M., Gurney, H., Craft, P., Boland, A., Simes, R., Toner, G. (2010), Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute. 102(16), 1253-62. [Abstract]
  • Kao, S., McCaughan, B., Muljono, A., Boyer, M. (2010), A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. Journal of Thoracic Oncology. 5(3), 405-406. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010), Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. Journal of the Society for Integrative Oncology. 8(2), 56-64. [Abstract]


  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009), Reply to A.D. Sasse et al. Journal of Clinical Oncology. 27(35), e254. [Abstract]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., Sutherland, R., Henshall, S., Horvath, L. (2009), Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research. 69(19), 7696-7703. [Abstract]
  • Yan, T., Boyer, M., Tin, M., Wong, D., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009), Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. The Journal of Thoracic and Cardiovascular Surgery. 138(3), 619-624. [Abstract]
  • Tattersall, M., Dear, R., Jansen, J., Shepherd, H., J Devine, R., G Horvath, L., Boyer, M. (2009), Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia. 191(4), 209-212. [Abstract]
  • Pezaro, C., Rosenthal, M., Gurney, H., Davis, I., Underhill, C., Boyer, M., Kotasek, D., Solomon, B., Toner, G. (2009), An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American journal of clinical oncology. 32(4), 338-41. [Abstract]
  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009), Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(20), 3277-83. [Abstract]
  • Simonella, L., O'Connell, D., Vinod, S., Delaney, G., Boyer, M., Esmaili, N., Hensley, M., Goldsbury, D., Supramaniam, R., Hui, A., Armstrong, B. (2009), No improvement in lung cancer care: The management of lung cancer in 1996 and 2002 in New South Wales. Internal medicine journal. 39(0), 453-8. [Abstract]
  • Yan, T., Boyer, M., Tin, M., Sim, J., Kennedy, C., McLean, J., Bannon, P., McCaughan, B. (2009), Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. The Annals of Thoracic Surgery. 87(5), 1552-1556. [Abstract]
  • Martin, R., Fulham, M., Shannon, K., Hughes, C., Gao, K., Milross, C., Tin, M., Jackson, M., Clifford, A., Boyer, M., O'Brien, C. (2009), Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head & neck. 31(0), 244-50. [Abstract]
  • Yan, T., Tin, M., Boyer, M., McLean, J., Bannon, P., McCaughan, B. (2009), Treatment Failure after Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Journal of Thoracic Disease. 1(1), 23-28.
  • Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009), Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC cancer. 9(1), 130. [Abstract]